p53 and ras mutations in Ewing's sarcoma

Kathrin Radig, Regine Schneider-Stock, Ingeborg Röse, Uwe Mittler, Yoshinao Oda, Albert Roessner

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The role of tumor suppressor genes and oncogenes in the development of Ewing's sarcoma has not yet been fully clarified. In this study, we analyzed the frequency of p53 tumor suppressor gene mutation in exons 4-8 by PCR-SSCP and direct sequencing, and the expression of p53-protein in Ewing's sarcoma (ES) by using immunohistochemistry. The overexpression of MDM2, which acts as a functional inactivator of p53, was studied by immunohistochemistry. In addition, a screening for point mutations in the hot spot regions codon 12 and 13 of exon 1 and codon 61 of exon 2 of ras-genes (H-ras, N-ras, K-ras) was performed. In one case, a p53 gene mutation could be confirmed in codon 238 of exon 7 (1/24). Overexpression of MDM2 was found in five cases; in ras-genes, no mutations were detected. Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event. However, their frequency is comparable to that of PNET, suggesting that the low incidence of these mutations in ES and PNET could be group-specific for tumors of neuroectodermal genesis.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalPathology Research and Practice
Volume194
Issue number3
DOIs
Publication statusPublished - Jan 1 1998

Fingerprint

Ewing's Sarcoma
ras Genes
Exons
Codon
Primitive Neuroectodermal Tumors
Mutation
Tumor Suppressor Genes
Immunohistochemistry
Neuroectodermal Tumors
Genetic Suppression
Single-Stranded Conformational Polymorphism
p53 Genes
Osteosarcoma
Oncogenes
Point Mutation
Pediatrics
Polymerase Chain Reaction
Incidence
Proteins

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Radig, K., Schneider-Stock, R., Röse, I., Mittler, U., Oda, Y., & Roessner, A. (1998). p53 and ras mutations in Ewing's sarcoma. Pathology Research and Practice, 194(3), 157-162. https://doi.org/10.1016/S0344-0338(98)80016-2

p53 and ras mutations in Ewing's sarcoma. / Radig, Kathrin; Schneider-Stock, Regine; Röse, Ingeborg; Mittler, Uwe; Oda, Yoshinao; Roessner, Albert.

In: Pathology Research and Practice, Vol. 194, No. 3, 01.01.1998, p. 157-162.

Research output: Contribution to journalArticle

Radig, K, Schneider-Stock, R, Röse, I, Mittler, U, Oda, Y & Roessner, A 1998, 'p53 and ras mutations in Ewing's sarcoma', Pathology Research and Practice, vol. 194, no. 3, pp. 157-162. https://doi.org/10.1016/S0344-0338(98)80016-2
Radig K, Schneider-Stock R, Röse I, Mittler U, Oda Y, Roessner A. p53 and ras mutations in Ewing's sarcoma. Pathology Research and Practice. 1998 Jan 1;194(3):157-162. https://doi.org/10.1016/S0344-0338(98)80016-2
Radig, Kathrin ; Schneider-Stock, Regine ; Röse, Ingeborg ; Mittler, Uwe ; Oda, Yoshinao ; Roessner, Albert. / p53 and ras mutations in Ewing's sarcoma. In: Pathology Research and Practice. 1998 ; Vol. 194, No. 3. pp. 157-162.
@article{6132f06be3834d4bb9b3b9e316b8b6bb,
title = "p53 and ras mutations in Ewing's sarcoma",
abstract = "The role of tumor suppressor genes and oncogenes in the development of Ewing's sarcoma has not yet been fully clarified. In this study, we analyzed the frequency of p53 tumor suppressor gene mutation in exons 4-8 by PCR-SSCP and direct sequencing, and the expression of p53-protein in Ewing's sarcoma (ES) by using immunohistochemistry. The overexpression of MDM2, which acts as a functional inactivator of p53, was studied by immunohistochemistry. In addition, a screening for point mutations in the hot spot regions codon 12 and 13 of exon 1 and codon 61 of exon 2 of ras-genes (H-ras, N-ras, K-ras) was performed. In one case, a p53 gene mutation could be confirmed in codon 238 of exon 7 (1/24). Overexpression of MDM2 was found in five cases; in ras-genes, no mutations were detected. Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event. However, their frequency is comparable to that of PNET, suggesting that the low incidence of these mutations in ES and PNET could be group-specific for tumors of neuroectodermal genesis.",
author = "Kathrin Radig and Regine Schneider-Stock and Ingeborg R{\"o}se and Uwe Mittler and Yoshinao Oda and Albert Roessner",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0344-0338(98)80016-2",
language = "English",
volume = "194",
pages = "157--162",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "3",

}

TY - JOUR

T1 - p53 and ras mutations in Ewing's sarcoma

AU - Radig, Kathrin

AU - Schneider-Stock, Regine

AU - Röse, Ingeborg

AU - Mittler, Uwe

AU - Oda, Yoshinao

AU - Roessner, Albert

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The role of tumor suppressor genes and oncogenes in the development of Ewing's sarcoma has not yet been fully clarified. In this study, we analyzed the frequency of p53 tumor suppressor gene mutation in exons 4-8 by PCR-SSCP and direct sequencing, and the expression of p53-protein in Ewing's sarcoma (ES) by using immunohistochemistry. The overexpression of MDM2, which acts as a functional inactivator of p53, was studied by immunohistochemistry. In addition, a screening for point mutations in the hot spot regions codon 12 and 13 of exon 1 and codon 61 of exon 2 of ras-genes (H-ras, N-ras, K-ras) was performed. In one case, a p53 gene mutation could be confirmed in codon 238 of exon 7 (1/24). Overexpression of MDM2 was found in five cases; in ras-genes, no mutations were detected. Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event. However, their frequency is comparable to that of PNET, suggesting that the low incidence of these mutations in ES and PNET could be group-specific for tumors of neuroectodermal genesis.

AB - The role of tumor suppressor genes and oncogenes in the development of Ewing's sarcoma has not yet been fully clarified. In this study, we analyzed the frequency of p53 tumor suppressor gene mutation in exons 4-8 by PCR-SSCP and direct sequencing, and the expression of p53-protein in Ewing's sarcoma (ES) by using immunohistochemistry. The overexpression of MDM2, which acts as a functional inactivator of p53, was studied by immunohistochemistry. In addition, a screening for point mutations in the hot spot regions codon 12 and 13 of exon 1 and codon 61 of exon 2 of ras-genes (H-ras, N-ras, K-ras) was performed. In one case, a p53 gene mutation could be confirmed in codon 238 of exon 7 (1/24). Overexpression of MDM2 was found in five cases; in ras-genes, no mutations were detected. Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event. However, their frequency is comparable to that of PNET, suggesting that the low incidence of these mutations in ES and PNET could be group-specific for tumors of neuroectodermal genesis.

UR - http://www.scopus.com/inward/record.url?scp=0031921885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031921885&partnerID=8YFLogxK

U2 - 10.1016/S0344-0338(98)80016-2

DO - 10.1016/S0344-0338(98)80016-2

M3 - Article

C2 - 9587933

AN - SCOPUS:0031921885

VL - 194

SP - 157

EP - 162

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 3

ER -